Bethanie Garside1, Jan Hoong Ho1,2, See Kwok1, Yifen Liu1, Shaishav Dhage2, Rachelle Donn3, Zohaib Iqbal1,2, Simon A Jones4, Handrean Soran5,6. 1. Lipid Research Group, Division of Cardiovascular Sciences, University of Manchester, Manchester, UK. 2. Cardiovascular Trials Unit, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Oxford Road, Manchester, M13 9WL, UK. 3. Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. 4. Manchester Centre for Genomic Medicine, St Marys Hospital, Manchester University NHS Foundation Trust, Manchester, UK. 5. Lipid Research Group, Division of Cardiovascular Sciences, University of Manchester, Manchester, UK. Handrean.Soran@mft.nhs.uk. 6. Cardiovascular Trials Unit, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Oxford Road, Manchester, M13 9WL, UK. Handrean.Soran@mft.nhs.uk.
Abstract
BACKGROUND: Enzyme replacement therapy (ERT) with olipudase alfa, a recombinant human acid sphingomyelinase (rhASM), is being developed to treat patients with ASM deficiency (ASMD), commonly known as Niemann-Pick disease (NPD) types A or B. This study assessed the effect of ERT on lipid parameters and inflammatory markers. METHODS: Serum and plasma samples from five adults with NPD type B (NPD-B) who received olipudase alfa ERT for 26 weeks were analysed. We also collected fasting blood samples from fifteen age- and sex-matched participants as reference and comparison group. We measured fasting lipid profile, apolipoproteins B48 and B100 (apoB48 and apoB100), apolipoprotein A1 (apoA1), proprotein convertase subtilisin/klexin type 9 (PCSK9) mass, oxidised low-density lipoprotein (oxLDL), small dense low-density lipoprotein cholesterol (sdLDL-C) and tumour necrosis factor α (TNF-α). RESULTS: Patients with NPD-B, compared with age and sex matched reference group, had higher triglycerides, PCSK9, apoB48, oxLDL and TNF-α and lower high density lipoprotein cholesterol (HDL-C) and apoA1. Treatment with ERT was associated with improved lipid parameters including total cholesterol, triglycerides, low density lipoprotein cholesterol (LDL-C), sdLDL-C, oxLDL and apoB100. Though there was an increase in apoA1, HDL-C was slightly reduced. TNF-α showed a reduction. ApoB100 decreased in parallel with a decrease in total serum PCSK9 mass after ERT. CONCLUSION: This study demonstrated that patients with NPD-B had a proatherogenic lipid profile and higher circulating TNF-α compared to reference group. There was an improvement in dyslipidaemia after olipudase alfa. It was possible that reductions in LDL-C and apoB100 were driven by reductions in TNF-α and PCSK9 following ERT.
BACKGROUND: Enzyme replacement therapy (ERT) with olipudase alfa, a recombinant human acid sphingomyelinase (rhASM), is being developed to treat patients with ASM deficiency (ASMD), commonly known as Niemann-Pick disease (NPD) types A or B. This study assessed the effect of ERT on lipid parameters and inflammatory markers. METHODS: Serum and plasma samples from five adults with NPD type B (NPD-B) who received olipudase alfa ERT for 26 weeks were analysed. We also collected fasting blood samples from fifteen age- and sex-matched participants as reference and comparison group. We measured fasting lipid profile, apolipoproteins B48 and B100 (apoB48 and apoB100), apolipoprotein A1 (apoA1), proprotein convertase subtilisin/klexin type 9 (PCSK9) mass, oxidised low-density lipoprotein (oxLDL), small dense low-density lipoprotein cholesterol (sdLDL-C) and tumour necrosis factor α (TNF-α). RESULTS: Patients with NPD-B, compared with age and sex matched reference group, had higher triglycerides, PCSK9, apoB48, oxLDL and TNF-α and lower high density lipoprotein cholesterol (HDL-C) and apoA1. Treatment with ERT was associated with improved lipid parameters including total cholesterol, triglycerides, low density lipoprotein cholesterol (LDL-C), sdLDL-C, oxLDL and apoB100. Though there was an increase in apoA1, HDL-C was slightly reduced. TNF-α showed a reduction. ApoB100 decreased in parallel with a decrease in total serum PCSK9 mass after ERT. CONCLUSION: This study demonstrated that patients with NPD-B had a proatherogenic lipid profile and higher circulating TNF-α compared to reference group. There was an improvement in dyslipidaemia after olipudase alfa. It was possible that reductions in LDL-C and apoB100 were driven by reductions in TNF-α and PCSK9 following ERT.
Authors: Szczepan Józefowski; Maciej Czerkies; Anna Łukasik; Alicja Bielawska; Jacek Bielawski; Katarzyna Kwiatkowska; Andrzej Sobota Journal: J Immunol Date: 2010-11-01 Impact factor: 5.422
Authors: Göran Walldius; Ingmar Jungner; Are H Aastveit; Ingar Holme; Curt D Furberg; Allan D Sniderman Journal: Clin Chem Lab Med Date: 2004 Impact factor: 3.694
Authors: Antonio Gomez-Muñoz; Natalia Presa; Ana Gomez-Larrauri; Io-Guané Rivera; Miguel Trueba; Marta Ordoñez Journal: Prog Lipid Res Date: 2015-12-15 Impact factor: 16.195
Authors: P J Barter; C M Ballantyne; R Carmena; M Castro Cabezas; M John Chapman; P Couture; J de Graaf; P N Durrington; O Faergeman; J Frohlich; C D Furberg; C Gagne; S M Haffner; S E Humphries; I Jungner; R M Krauss; P Kwiterovich; S Marcovina; C J Packard; T A Pearson; K Srinath Reddy; R Rosenson; N Sarrafzadegan; A D Sniderman; A F Stalenhoef; E Stein; P J Talmud; A M Tonkin; G Walldius; K M S Williams Journal: J Intern Med Date: 2006-03 Impact factor: 8.989